Table 1 Baseline characteristics
Author | year | country | DET | DIT | NO.TC | NO.TTC | DM | ES | AM |
|---|---|---|---|---|---|---|---|---|---|
Caussy | 2019 | USA | cohort study | cirrhosis | 26 | 72 | 16S rRNA | 27 Genus | MRI |
Dong | 2020 | USA | control trial | fibrosis | 50 | 75 | 16S rRNA | 26 Genus | UE |
Chen | 2020 | CHN | control trial | cirrhosis | 25 | 97 | 16S rRNA | 32 Genus | MRI + CT |
Gyu Oh | 2020 | USA | cohort study | cirrhosis | 27 | 81 | Shotgun metagenomic | 37 Genus | Liver Biopsy |
Loomba | 2017 | USA | cohort study | fibrosis | 14 | 86 | Whole genome shotgun | 37 Genus | Liver Biopsy |
Lang 1A | 2020 | USA | cohort study | cirrhosis | 44 | 73 | Shotgun metagenomic | 420 Species | Liver Biopsy |
Lang 1B | 2020 | USA | cohort study | fibrosis | 29 | 73 | Shotgun metagenomic | 420 Species | Liver Biopsy |
Lang 2 | 2020 | DEU | cohort study | fibrosis | 13 | 96 | 16S rRNA | 37 Genus | Liver Biopsy |
Lapidot | 2020 | ISR | control trial | cirrhosis | 68 | 95 | 16S rRNA | / | Based on histological and/or clinical findings |
Lee | 2020 | Kr | control trial | fibrosis | 64 | 117 | 16S rRNA | 2 Family | Liver Biopsy |
Schwimmer | 2019 | USA | control trial | cirrhosis | 87 | 124 | 16S rRNA and Metagenomics | 3 Phylum | Liver Biopsy |